Please use this identifier to cite or link to this item:
Title: Intestinal failure and transplant: The Australian experience (2009 to 2014)
Austin Authors: Chapman, Brooke ;De Cruz, Peter;Jones, Robert M ;Testro, Adam G 
Affiliation: Nutrition and Dietetics Department, Austin Health, Heidelberg, Victoria, Australia
Liver and Intestinal Transplant Unit, Royal Children's Hospital, Melbourne, Victoria, Australia
Liver and Intestinal Transplant Unit, Austin Health, Heidelberg, Victoria, Australia
Issue Date: Mar-2016
Publication information: Transplantation Proceedings 2016; 48(2): 463-467
Abstract: BACKGROUND: A joint adult and pediatric intestinal transplant (ITx) program for Australia was developed in 2009 to provide life-saving ITx to patients with irreversible intestinal failure (IF). We aimed to analyze the outcomes of patients treated by our service over the past 5 years. METHODS: A retrospective medical record review was conducted on all IF patients referred to our service. Patient demographics, underlying disease, nutrition support, TPN complications, and current transplant program status were evaluated. RESULTS: Fifty-seven patients (35 adults, 40.4 ± 12.4 years; 22 children, 6.3 ± 4.3 years) throughout Australia and New Zealand have been referred. Leading causes of IF were short bowel syndrome followed by pseudo-obstruction. Forty patients (70%) exhibited at least 1 life-threatening complication of PN at referral: liver failure, impending loss of venous access, and/or recurrent line sepsis. Three patients have undergone ITx with 100% survival (median follow-up, 1161 days). Four patients (8%) are listed for transplant, 6 patients (12%) are awaiting transplant assessment, and 4 patients (8%) have died (2 while awaiting transplantation, 2 during assessment period). Causes of death included sepsis and intracranial bleed. Two-thirds of all referred patients (n = 40) were deferred or rejected from wait-listing. CONCLUSIONS: After 5 years of establishing the first dedicated ITx program in Australia and New Zealand, early results indicate that ITx is an available and life-saving option for IF patients in these countries. Current barriers to ITx in Australia include a shortage of appropriate donors and a high rate of donor-specific antibodies among potential recipients. Growing awareness of the service and early referral to assist appropriate patient selection will aid in the program's success.
DOI: 10.1016/j.transproceed.2015.09.071
PubMed URL:
Type: Journal Article
Subjects: Australia
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 5, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.